{"id":"NCT00562354","sponsor":"Pfizer","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years","officialTitle":"A Phase 3, Open-Label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13vPnC When Administered to Healthy Japanese Adults Aged >= 65 Years and 50 to 64 Years in Japan Who Have Not Received a Previous Dose of 23-Valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2007-11-22","resultsPosted":"2011-11-11","lastUpdate":"2011-11-11"},"enrollment":271,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Healthy"],"interventions":[{"type":"BIOLOGICAL","name":"13vPnC","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate (13vPnC) vaccine in healthy Japanese adults aged \\>= 50 years.","primaryOutcome":{"measure":"Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Overall Population","timeFrame":"1 month after vaccination","effectByArm":[{"arm":"13vPnC Overall Population (50 to 64 and â‰¥65 Years of Age)","deltaMin":124,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":["25424792"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":134},"commonTop":["Limitation of arm movement: any","Limitation of arm movement: mild","Pain: any","Injection site pain","Pain: mild"]}}